Compare GAUZ & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | IMRN |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.7M |
| IPO Year | 2019 | 2016 |
| Metric | GAUZ | IMRN |
|---|---|---|
| Price | $5.76 | $0.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.6K | 22.9K |
| Earning Date | 11-13-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.89 | $16.39 |
| Revenue Next Year | $72.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.68 |
| 52 Week High | $8.52 | $1.99 |
| Indicator | GAUZ | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 32.67 |
| Support Level | $0.48 | $0.73 |
| Resistance Level | $8.52 | $0.89 |
| Average True Range (ATR) | 0.77 | 0.07 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 77.96 | 8.30 |
Gauzy Ltd is a fully integrated light and vision control company. Its products products include suspended particle device, or SPD, and liquid crystal, or LC, materials for smart glass applications, and AI-powered advanced driver assistance systems, or ADAS, solutions including camera monitoring systems, or CMS. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.